ATE435303T1 - Verfahren und zusammensetzungen in verbindung mit gen-silencing - Google Patents

Verfahren und zusammensetzungen in verbindung mit gen-silencing

Info

Publication number
ATE435303T1
ATE435303T1 AT03784781T AT03784781T ATE435303T1 AT E435303 T1 ATE435303 T1 AT E435303T1 AT 03784781 T AT03784781 T AT 03784781T AT 03784781 T AT03784781 T AT 03784781T AT E435303 T1 ATE435303 T1 AT E435303T1
Authority
AT
Austria
Prior art keywords
stranded rna
double
fragments
gene silencing
sequences
Prior art date
Application number
AT03784781T
Other languages
English (en)
Inventor
George Tzertzinis
George Feehery
Corinna Tuckey
Christopher Noren
Larry Mcreynolds
Original Assignee
New England Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs Inc filed Critical New England Biolabs Inc
Application granted granted Critical
Publication of ATE435303T1 publication Critical patent/ATE435303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
AT03784781T 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing ATE435303T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40276902P 2002-08-12 2002-08-12
US40754302P 2002-08-30 2002-08-30
US46754103P 2003-05-02 2003-05-02
PCT/US2003/022540 WO2004015062A2 (en) 2002-08-12 2003-07-18 Methods and compositions relating to gene silencing

Publications (1)

Publication Number Publication Date
ATE435303T1 true ATE435303T1 (de) 2009-07-15

Family

ID=31721504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784781T ATE435303T1 (de) 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing

Country Status (8)

Country Link
US (2) US7700758B2 (de)
EP (1) EP1552018B1 (de)
JP (1) JP4339852B2 (de)
CN (1) CN1685063B (de)
AT (1) ATE435303T1 (de)
AU (1) AU2003256615A1 (de)
DE (1) DE60328214D1 (de)
WO (1) WO2004015062A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP1537227B1 (de) * 2002-05-31 2010-02-17 The Regents Of The University Of California Verfahren zur wirksamen rna-interferenz in säugerzellen
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20050060771A1 (en) * 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
US20050059019A1 (en) * 2003-09-11 2005-03-17 Sven Bulow Gene-related RNAi transfection method
US7695964B2 (en) 2004-01-23 2010-04-13 New England Biolabs, Inc. Compositions and methods for generating short double-stranded RNA using mutated RNAse III
JPWO2005095647A1 (ja) * 2004-03-31 2008-02-21 タカラバイオ株式会社 ｓｉＲＮＡのスクリーニング方法
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
WO2006000410A2 (en) * 2004-06-23 2006-01-05 Bayer Bioscience N.V. Method for identifying nucleic capable of modulating a gene in a biological system
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
CN101405408A (zh) 2006-01-18 2009-04-08 通用医疗公司 增强淋巴功能的方法
ES2685802T3 (es) 2006-05-25 2018-10-11 Biogen Ma Inc. Antagonista de VLA-1 para su utilización en el tratamiento de un accidente cerebrovascular
PT2056845T (pt) 2006-08-08 2017-11-17 Rheinische Friedrich-Wilhelms-Universität Bonn Estrutura e uso de oligonucleótidos com fosfato 5
MX2009008105A (es) * 2007-01-29 2010-03-03 Wyeth Corp Ligando de inmunofilina ds y metodos para modular la inmunofilina y la actividad de canal de calcio.
RU2009141965A (ru) 2007-04-16 2011-05-27 Момента Фармасьютикалз, Инк. (Us) Определенные продукты гликопротеина и способы их производства
US20110060135A1 (en) * 2007-11-29 2011-03-10 New England Biolabs, Inc. Selective Purification of Small RNAs from Mixtures
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
HUE061548T2 (hu) 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
ES2704126T3 (es) 2011-08-23 2019-03-14 Found Medicine Inc Moléculas de fusión KIF5B-RET y usos de las mismas
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
CA3163776A1 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
EP2983804A4 (de) * 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
RS62529B1 (sr) 2013-07-11 2021-11-30 Modernatx Inc Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
AU2014290044B2 (en) 2013-07-17 2020-10-29 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
EP3052511A4 (de) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynukleotidmoleküle und verwendungen davon
EP3157573A4 (de) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nukleinsäuremoleküle und verwendungen davon
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
EP3349773A4 (de) 2015-09-14 2019-05-01 Cincinnati Children's Hospital Medical Center Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
DK3350333T3 (da) 2015-09-17 2022-01-31 Modernatx Inc Polynukleotider, der indeholder en stabiliserende haleregion
CN114395624A (zh) 2016-02-29 2022-04-26 基因泰克公司 用于癌症的治疗和诊断方法
AU2017225869A1 (en) 2016-02-29 2018-09-06 Foundation Medicine, Inc. Methods of treating cancer
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
SG11201811704SA (en) 2016-07-13 2019-01-30 Biogen Ma Inc Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
CA3102135A1 (en) * 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
JP2022500427A (ja) 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗ｃ５剤の投与
CN111073885A (zh) * 2019-12-31 2020-04-28 江苏耀海生物制药有限公司 一种应用于双链dna片段的纯化方法
CN112626152A (zh) * 2020-12-18 2021-04-09 深圳大学 siRNA的制备方法
AU2022282559A1 (en) * 2021-05-26 2024-01-04 Etherna Immunotherapies Nv Method to reduce double stranded rna by-product formation
CN113621686A (zh) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 一种适用于多种病原微生物的检测方法
WO2024045192A1 (en) * 2022-09-02 2024-03-07 Xiaomo Biotech Limited Inclusion body mediated method for double-stranded rna producing
WO2025049599A1 (en) 2023-08-29 2025-03-06 President And Fellows Of Harvard College Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
EP1147204A1 (de) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
EP1272630A2 (de) 2000-03-16 2003-01-08 Genetica, Inc. Methoden und zusammensetzungen zur interferenz durch rna
JP2003527856A (ja) 2000-03-17 2003-09-24 ベニテック オーストラリア リミテッド 遺伝子のサイレンシング
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20020132346A1 (en) 2001-03-08 2002-09-19 Jose Cibelli Use of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
EP1537227B1 (de) * 2002-05-31 2010-02-17 The Regents Of The University Of California Verfahren zur wirksamen rna-interferenz in säugerzellen

Also Published As

Publication number Publication date
DE60328214D1 (de) 2009-08-13
US20080206835A1 (en) 2008-08-28
CN1685063B (zh) 2011-12-21
US20040038278A1 (en) 2004-02-26
WO2004015062A2 (en) 2004-02-19
WO2004015062A3 (en) 2005-02-24
EP1552018A4 (de) 2007-11-21
EP1552018A2 (de) 2005-07-13
JP4339852B2 (ja) 2009-10-07
AU2003256615A8 (en) 2004-02-25
US7700758B2 (en) 2010-04-20
AU2003256615A1 (en) 2004-02-25
EP1552018B1 (de) 2009-07-01
CN1685063A (zh) 2005-10-19
JP2005535356A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE435303T1 (de) Verfahren und zusammensetzungen in verbindung mit gen-silencing
Van Dijk et al. Library preparation methods for next-generation sequencing: tone down the bias
WO2004046320A3 (en) METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS
DE60332873D1 (de) Rolling-circle rna-amplifikation
WO2004058940A3 (en) Sirna-mediated gene silencing
Li et al. Identification and characterization of microRNAs in the spleen of common carp immune organ
ATE542918T1 (de) Verfahren zur quantifizierung von mikro-rnas und kleinen interferenz-rnas
EP1750771A4 (de) Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung
AU2003294447A8 (en) Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
PL1687435T3 (pl) Odporność na owady z użyciem hamowania ekspresji genów
Zhang et al. MicroRNA profile analysis on duck feather follicle and skin with high-throughput sequencing technology
DE60331321D1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
AR039717A1 (es) Construcciones de arn de intrones cadena doble y usos de las mismas
DE602006017192D1 (de) Verfahren zur herstellung von oligonukleotiden
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
US20140128292A1 (en) Methods for improving ligation steps to minimize bias during production of libraries for massively parallel sequencing
WO2005042705A3 (en) Short interfering rna and micro-rna compounds and methods of designing, making and using the same
PE20212248A1 (es) Molecula oligomerica de acido nucleico y uso de esta
DE602005022443D1 (de) Schnelle synthese von oligonukleotiden
Laganà et al. Identification of general and heart-specific miRNAs in sheep (Ovis aries)
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
WO2004094616A3 (en) Silencing transcription by methylation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties